April 2, 2025 C-Path’s Stephenson Appears on Xtalks’ Life Science Podcast to Talk Future of Drug Development in Parkinson’s, Alzheimer’s C-Path's Diane Stephenson recently appeared on the Xtalks Life Science Podcast...
March 10, 2025 C-Path’s Critical Path for Parkinson’s Consortium Welcomes CND Life Sciences C-Path is excited to welcome CND Life Sciences as the newest member of it Critical Path for Parkinson’s (CPP)...
August 12, 2024 C-Path Welcomes CuraSen As Newest CPP Member C-Path is thrilled to welcome CuraSen Therapeutics as the newest member of its Critical Path for Parkinson’s Consortium.
First-ever biomarker qualified for Parkinson’s is a vital step toward improved clinical trials FOR IMMEDIATE RELEASE Contact: Kissy Black 615.298.1144 kissyblack@lotosnile.com Tucson, AZ — July 26, 2018 – The Criti
“Improving Clinical Trials to Deliver Better Treatments,” as featured in the Spring 2018 edition of “Progress, the research magazine of Parkinson’s UK”
April 28, 2018 Dr. Stephenson’s presentation at University of Texas Health, San Antonio, The Perry and Ruby Stevens Parkinson’s Disease Center of Excellence: “Critical Path for Parkinson’s Collaboration to Enable Patient Focused Drug Development and Precision Medicine”
Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson’s Disease Clinical Trials: A Disease Progression Modeling Analysis Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone J, Corrigan B, Bani M, Muglia P, Watson IA, Kern VD, Sheveleva E, Marek K,
The FDA is Listening: Integrating the Voice of the Patient in Drug Development for Parkinson’s and Huntington’s Diseases
The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
